Sara joined Roivant Sciences in January 2019 to lead Biotech investments in Europe; she serves as Chairperson in several Roivant portfolio companies. Before Roivant, Sara was Principal with Sofinnova Partners in Paris, an independent venture capital firm based in Paris specialized in the life sciences sector. At Sofinnova, Sara was involved in the following investments: Delinia Bio (sold to Celgene for $875M in Jan 2017), ProQR Therapeutics [PRQR], Auris Medical [EARS], MedDay Pharma, ObsEva [OBSV], Enyo Pharma, Asceneuron, MyTomorrows, TrophyNOD, Leucid Bio and Comet Therapeutics. She represented Sofinnova on the Board of Delinia Bio, Comet Therapeutics, TrophyNOD, MedDay and Enyo Pharma. Prior to joining Sofinnova Partners in 2013, Sara was an associate in the M&A team at Onyx Pharmaceuticals (now Amgen) in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space. Sara spent 7 years in the Pharmaceutical industry with Solvay and Abbott Laboratories (now Abbvie) as a Medicinal Chemist in The Netherlands. During her time in drug development, Sara worked on preclinical programmes for several central nervous system indications, contributing to the submission of 3 IND packages: SLV354 (in Phase 2, Abbvie), SLV351 (in Phase 1, Pfizer), SLV338 (in Phase 1, Abbvie). Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed third-generation several transition state inhibitors for the enzyme PNP. Sara received her PhD in Chemistry from the University of Manchester, United Kingdom. She has published sixteen peer-reviewed articles and 1 patent. In addition, Sara also holds an MBA from INSEAD with major in Finance.